Immunovia (IMMNOV.ST)

Executive Summary

Immunovia is a Swedish diagnostics company dedicated to early detection of pancreatic cancer, one of the deadliest cancers with a five-year survival rate of just 13% due to late diagnosis. Its proprietary IMMray PanCan-d blood test aims to identify pancreatic cancer at earlier, more treatable stages by detecting specific biomarkers. The company addresses a critical unmet need, as most pancreatic cancer cases are diagnosed when curative surgery is no longer an option, leading to poor outcomes. Immunovia's technology has the potential to significantly improve survival rates through routine screening of high-risk populations, such as those with a family history or new-onset diabetes. The company is privately held with a valuation of approximately $134 million and trades on the Stockholm Stock Exchange under the ticker IMMNOV.ST. While Immunovia has not yet generated commercial revenue, it is progressing toward regulatory approvals and clinical validation. Key milestones include ongoing discussions with the FDA for a potential 510(k) clearance and the publication of clinical study data. If successful, IMMray PanCan-d could become the first blood-based test for early pancreatic cancer screening, addressing a market opportunity spanning millions of at-risk individuals annually. The company's near-term success hinges on regulatory outcomes and adoption by healthcare providers.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance Decision for IMMray PanCan-d60% success
• H2 2026Publication of Pivotal Clinical Validation Study Results75% success
• H2 2026Strategic Partnership with Major Cancer Center or Diagnostic Lab50% success